Agentic AI for Large Contract Research Organizations

Maxis AI provides Agentic AI for large contract research organizations through the industry's first AI Workforce for Clinical Trials. It supports supervised execution across study startup, RBQM, clinical data management, statistical programming, medical writing, and portfolio oversight. Instead of replacing delivery teams, the AI Workforce executes structured operational work within defined workflow boundaries while human experts validate critical decisions. This enables large CROs to improve delivery consistency, support 100–300+ concurrent clinical trials, increase biometrics efficiency, and strengthen sponsor oversight without proportional headcount growth.

Agentic AI for global contract research organizations improves delivery performance by standardizing execution across multiple studies, sponsors, and geographies. AI agents perform structured operational tasks consistently, while human validation checkpoints ensure regulatory compliance and sponsor confidence. This reduces execution variability, accelerates database readiness, improves RBQM activities, and helps delivery teams meet contractual milestones more predictably. By improving throughput without continuously increasing staffing, global CROs can protect study margins while maintaining high-quality delivery across large clinical trial portfolios.

No. Maxis AI is designed to augment—not replace—clinical delivery teams. The AI Workforce performs repetitive, rules-based operational work, allowing experienced professionals to focus on sponsor collaboration, clinical oversight, quality review, and exception management. Human validation remains part of every governed workflow, ensuring outputs are traceable, auditable, and suitable for regulated clinical research. This supervised execution model helps organizations scale delivery capacity while preserving the expertise and decision-making responsibilities of their clinical operations teams.

Yes. Agentic AI for global contract research organizations is designed to operate within sponsor-defined workflows, governance models, and technology environments. Workflow boundaries, approval checkpoints, output standards, and escalation paths are configured to align with each sponsor's operational requirements. This enables AI-supported execution without disrupting existing clinical systems or established quality processes. The result is consistent execution across multiple sponsor engagements while maintaining compliance, auditability, and contractual delivery standards throughout the clinical trial lifecycle.

Yes. Most organizations begin with a single operational workflow such as RBQM, clinical data management, statistical programming, or data quality oversight. Once governance, performance metrics, and validation processes are established, the same execution framework can be expanded across additional therapeutic areas, delivery units, or sponsor programs. This phased deployment approach minimizes operational risk while allowing organizations to scale AI adoption across broader clinical operations as confidence and measurable outcomes increase.

Large CROs manage increasingly complex clinical portfolios where operational consistency directly influences delivery timelines, sponsor satisfaction, and profitability. Agentic AI for large contract research organizations provides supervised execution that helps standardize repetitive workflows across 100–300+ concurrent clinical trials while maintaining human oversight. By improving execution quality, reducing operational bottlenecks, and increasing visibility across delivery teams, organizations can scale clinical operations more predictably without proportional workforce expansion. This strengthens delivery performance, improves study margins, and provides sponsors with greater confidence in execution across global clinical programs.